Arunkumar Modi
Concepts (75)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 3 | 2024 | 183 | 1.080 |
Why?
| Burkitt Lymphoma | 2 | 2023 | 28 | 1.020 |
Why?
| Cytarabine | 1 | 2021 | 39 | 0.790 |
Why?
| Vancomycin | 1 | 2021 | 82 | 0.750 |
Why?
| Fever | 1 | 2021 | 117 | 0.740 |
Why?
| Bacteremia | 1 | 2021 | 92 | 0.730 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 105 | 0.720 |
Why?
| Hematopoietic Stem Cell Transplantation | 4 | 2023 | 553 | 0.570 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 91 | 0.570 |
Why?
| Receptors, Fc | 2 | 2024 | 10 | 0.430 |
Why?
| Thrombopoietin | 2 | 2024 | 11 | 0.430 |
Why?
| Anemia, Aplastic | 2 | 2024 | 12 | 0.430 |
Why?
| Myelodysplastic Syndromes | 2 | 2024 | 80 | 0.410 |
Why?
| Recombinant Fusion Proteins | 2 | 2024 | 182 | 0.410 |
Why?
| Child | 12 | 2024 | 6824 | 0.330 |
Why?
| Receptors, Thrombopoietin | 2 | 2024 | 6 | 0.250 |
Why?
| Child, Preschool | 6 | 2024 | 3853 | 0.240 |
Why?
| Lymphoma, B-Cell | 1 | 2024 | 63 | 0.230 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 10 | 0.230 |
Why?
| Young Adult | 5 | 2024 | 3936 | 0.220 |
Why?
| Anemia, Dyserythropoietic, Congenital | 1 | 2022 | 1 | 0.210 |
Why?
| Catheter-Related Infections | 1 | 2022 | 50 | 0.200 |
Why?
| Central Venous Catheters | 1 | 2022 | 27 | 0.200 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2021 | 37 | 0.200 |
Why?
| Graft vs Host Disease | 1 | 2022 | 74 | 0.200 |
Why?
| Neutropenia | 1 | 2022 | 117 | 0.190 |
Why?
| Bacterial Infections | 1 | 2022 | 98 | 0.190 |
Why?
| Catheterization, Central Venous | 1 | 2022 | 87 | 0.190 |
Why?
| Adolescent | 5 | 2024 | 6340 | 0.190 |
Why?
| Sepsis | 1 | 2022 | 220 | 0.170 |
Why?
| Prognosis | 2 | 2021 | 1952 | 0.160 |
Why?
| Infant | 2 | 2021 | 3551 | 0.140 |
Why?
| Humans | 13 | 2024 | 49827 | 0.140 |
Why?
| Follow-Up Studies | 1 | 2021 | 2179 | 0.130 |
Why?
| Male | 8 | 2024 | 25093 | 0.130 |
Why?
| Anti-Bacterial Agents | 1 | 2021 | 743 | 0.130 |
Why?
| Retrospective Studies | 3 | 2022 | 6117 | 0.130 |
Why?
| Female | 7 | 2024 | 26329 | 0.120 |
Why?
| Adult | 4 | 2024 | 13160 | 0.120 |
Why?
| Infant, Newborn | 1 | 2021 | 2744 | 0.120 |
Why?
| Receptors, Antigen, T-Cell | 2 | 2024 | 50 | 0.120 |
Why?
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 9 | 0.120 |
Why?
| Leukemia, Myelomonocytic, Juvenile | 1 | 2013 | 17 | 0.110 |
Why?
| GTP Phosphohydrolases | 1 | 2013 | 31 | 0.110 |
Why?
| Neoplasms, Multiple Primary | 1 | 2013 | 44 | 0.110 |
Why?
| Mutation, Missense | 1 | 2013 | 103 | 0.110 |
Why?
| Antineoplastic Agents | 1 | 2021 | 1172 | 0.110 |
Why?
| Recurrence | 2 | 2024 | 651 | 0.100 |
Why?
| Membrane Proteins | 1 | 2013 | 342 | 0.100 |
Why?
| Neoplasms | 1 | 2021 | 1233 | 0.090 |
Why?
| Transplantation Conditioning | 2 | 2022 | 83 | 0.080 |
Why?
| Quality of Life | 2 | 2024 | 833 | 0.070 |
Why?
| Selection Bias | 1 | 2024 | 15 | 0.060 |
Why?
| Risk Factors | 2 | 2022 | 3619 | 0.050 |
Why?
| Immunotherapy, Adoptive | 1 | 2024 | 154 | 0.050 |
Why?
| Treatment Outcome | 2 | 2024 | 5138 | 0.050 |
Why?
| Pilot Projects | 1 | 2024 | 699 | 0.050 |
Why?
| Clinical Trials as Topic | 1 | 2024 | 460 | 0.050 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 1 | 2021 | 18 | 0.050 |
Why?
| Transplantation, Homologous | 1 | 2021 | 138 | 0.050 |
Why?
| Hematopoiesis | 1 | 2021 | 71 | 0.050 |
Why?
| Reading | 1 | 2021 | 82 | 0.050 |
Why?
| Survivors | 1 | 2021 | 125 | 0.050 |
Why?
| Doxorubicin | 1 | 2022 | 230 | 0.050 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 141 | 0.050 |
Why?
| Exercise Therapy | 1 | 2021 | 98 | 0.050 |
Why?
| Graft Rejection | 1 | 2021 | 159 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2021 | 469 | 0.040 |
Why?
| Bone Marrow | 1 | 2021 | 362 | 0.040 |
Why?
| Exercise | 1 | 2021 | 490 | 0.040 |
Why?
| Prospective Studies | 1 | 2021 | 2344 | 0.030 |
Why?
| Cytogenetic Analysis | 1 | 2013 | 82 | 0.030 |
Why?
| Bone Marrow Transplantation | 1 | 2013 | 116 | 0.030 |
Why?
| Aged | 1 | 2021 | 9272 | 0.020 |
Why?
| Middle Aged | 1 | 2021 | 11997 | 0.020 |
Why?
|
|
Modi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Same Department
People who are also in this person's primary department.
|